Food and Beverage Production

Kirin Holdings Company, Limited

Kirin Holdings and Immunosens Collaborate to Launch Self-Testing Service

2503

Kirin Holdings Co. (OTCMKTS:KNBWY) experienced a significant decline in short interest, dropping 16.8% in March to 18,027 shares. Currently, only 0.0% of the company's stock is sold short, with a days-to-cover ratio of 0.2 days based on an average daily volume of 78,747 shares. The stock opened at $16.52, with a market cap of $13.38 billion and a P/E ratio of 13.54. Analysts have downgraded Kirin from a "buy" to a "hold" rating, despite the company reporting better-than-expected quarterly earnings.

Market Beat

Kirin Holdings Co. (OTCMKTS:KNBWY) Sees Large Decrease in Short Interest

Kirin Holdings Company (TSE:2503) has seen a recent share price decline of 2.9% in one day and 2.7% in a month, despite a 26.39% total shareholder return over the past year. Currently trading at ¥2,540, it is 5% below analyst targets and 40% below intrinsic estimates, with a P/E ratio of 13.9x, indicating potential undervaluation compared to industry averages. However, slower revenue growth and reliance on mature products may limit future value. Analysts suggest the shares are undervalued based on both P/E and discounted cash flow models, indicating a potential value opportunity for investors.

Simplywall

Assessing Kirin Holdings Company (TSE:2503) Valuation After Recent Share Price Pullback

4151

Kirin Holdings Company (TSE:2503) is gaining attention after its subsidiary Kyowa Kirin partnered with Cowellnex and Metagen to develop gut microbiota health solutions. The company has seen an 8.44% share price increase over 30 days and a 29.85% return over the past year. With a P/E ratio of 14.2x, below industry averages, Kirin appears undervalued compared to its estimated fair value of ¥4,545 per share. However, risks remain if earnings decline or the health initiative falters. Investors are encouraged to explore further opportunities in undervalued stocks.

Kyowa Kirin Co., Ltd.

Assessing Kirin Holdings Company (TSE:2503) Valuation After New Gut Microbiota Health Collaboration

01876

515170

159736

TAP.A

FTXG

Anheuser-Busch InBev S.A. ADR (BUD) fell 2.49% to $73.71 on Thursday, marking its fourth consecutive day of losses. The stock underperformed the market, with the S&P 500 down 0.56% and the Dow Jones down 1.61%. The ADR is now 9.62% below its 52-week high of $81.56. Despite the losses, it outperformed competitors like Kirin Holdings, San Miguel Corp, and Compania Cervecerias Unidas, which saw larger declines. Trading volume was 1.9 million, below the 50-day average of 2.2 million.

Dow Jones

BUD APAC

CIA Cervecerias Unidas

ChinaAMC CSI Food & Beverage Sub-Industry ETF

Tianhong CSI Food and Beverage ETF

VG Consumer Stap

Molson Coors Beverage

iShares US Consumer Staples ETF

First Trust NASDAQ Food & Beverage

SPDR FD Consumer Staples

Anheuser-Busch InBev S.A. ADR Falls Thursday, Underperforms Market

Cowellnex Co., Ltd. and Metagen, Inc. will begin a collaborative research project in Japan in February 2026. This initiative aims to develop new test items based on gut microbiota data from Japanese subjects and create an algorithm for food recommendations. The partnership, involving Kirin Holdings and Kyowa Kirin, marks a significant advancement in gut health research and development.

Unusual Whales

Cowellnex and Metagen launch research project in Japan to develop new test items based on gut microbiota data, starting in Feb 2026.

Wall Street Zen downgraded Kirin (OTCMKTS:KNBWY) from a "buy" to a "hold" rating. On Tuesday, Kirin's stock rose by $0.43 to $16.13, with a market cap of $13.07 billion. The company reported $0.42 EPS, exceeding estimates of $0.34, but revenue of $4.02 billion fell short of the $4.16 billion expectation. Kirin's twelve-month stock range is $12.40 to $16.20, and analysts predict 1.12 EPS for the current year.

Kirin (OTCMKTS:KNBWY) Stock Rating Lowered by Wall Street Zen

Kirin Holdings and Immunosens have partnered to create a self-testing service that visualizes immune status through urinary IgA. This initiative is supported by the KIRIN HEALTH INNOVATION FUND, established in collaboration with Global Brain Corporation. The partnership signifies a major advancement in developing innovative healthcare solutions.

Kirin and Immunosens collaborate on self-testing service using urinary IgA to visualize immune status. Joint funding from Kirin and Global Brain Corporation.

Japanese brewer Kirin Holdings is selling its Four Roses bourbon brand to E&J Gallo Winery for up to $775 million as it shifts focus towards healthcare amid a cooling US whisky market. The deal, expected to finalize in Q2 of fiscal 2026, comes as bourbon sales decline due to reduced consumer spending. Kirin aims for its health business to constitute 20% of total sales by 2030, having recently acquired companies in the health sector. Kirin shares rose 1.5% following the announcement.

Businesstimes News

Japan’s Kirin sells Four Roses bourbon as US whisky market cools

Kirin Holdings Company, Limited(2503.JP)

Kirin Holdings Co. (OTCMKTS:KNBWY) Sees Large Decrease in Short Interest

Assessing Kirin Holdings Company (TSE:2503) Valuation After Recent Share Price Pullback

Assessing Kirin Holdings Company (TSE:2503) Valuation After New Gut Microbiota Health Collaboration

Anheuser-Busch InBev S.A. ADR Falls Thursday, Underperforms Market

Cowellnex and Metagen launch research project in Japan to develop new test items based on gut microbiota data, starting in Feb 2026.